GLP-1RA and incretin therapies combined with lifestyle interventions cut body weight by 10 kg in adults with obesity
Background
The global prevalence of overweight and obesity continues to rise, necessitating effective management strategies. While glucagon-like peptide-1 receptor agonists (GLP-1RAs) and other incretin-based therapies have emerged as powerful tools, their full clinical value extends beyond simple weight loss, encompassing changes in fat mass, lean mass, physical function, and cardiometabolic risk. Understanding how these therapies perform when delivered within comprehensive lifestyle interventions is crucial to optimize patient outcomes and address the multifaceted nature of obesity management.
Study Design
This systematic review and meta-analysis evaluated GLP-1RA- and incretin-based therapies delivered within lifestyle interventions. Researchers searched PubMed/MEDLINE, Web of Science, Scopus, CINAHL, SPORTDiscus, and CENTRAL databases from inception. Records were deduplicated, and risk of bias was assessed using the Cochrane RoB 2 tool. Random-effects meta-analyses were estimated using restricted maximum likelihood with Hartung-Knapp adjustment to pool data from eligible studies, focusing on body-weight reduction as the primary endpoint.
Results
From an initial 1651 identified records, 48 reports corresponding to 35 independent trials were retained for qualitative synthesis. The primary kilogram-scale meta-analysis included eight independent comparisons. This analysis showed significantly greater body-weight reduction with GLP-1RA/incretin-based therapy delivered within a lifestyle background compared to placebo/control. The mean difference (MD) was -10.08 kg (95% confidence interval [CI] -12.76 to -7.39; 95% prediction interval [PI] -17.86 to -2.29; I² = 95.6%). Percentage body-weight change was analyzed separately across 11 independent comparisons. This also favored GLP-1RA/incretin-based therapy, demonstrating a mean reduction of -9.53 percentage points (95% CI -11.92 to -7.14; 95% PI -17.58 to -1.48; I² = 95.4%).
Key Findings
- GLP-1RA/incretin therapies with lifestyle interventions led to a -10.08 kg mean body weight reduction vs. control.
- Percentage body weight reduction was -9.53 percentage points with GLP-1RA/incretin therapies plus lifestyle.
- The primary meta-analysis included eight independent comparisons for kilogram-scale weight loss.
- High statistical heterogeneity (I² > 95%) was present in both primary analyses.
Why It Matters
This meta-analysis reinforces the substantial efficacy of GLP-1RA and incretin-based therapies for weight loss, particularly when integrated with lifestyle interventions. For individuals managing overweight or obesity, this suggests that combining pharmacological support with dietary and exercise changes yields superior outcomes. The findings underscore the importance of a holistic approach, where these powerful peptides act synergistically with behavioral modifications. While specific protocols were not detailed, the consistent benefit across studies highlights that these therapies are most effective as part of a comprehensive strategy, rather than a standalone solution. This supports current clinical guidelines advocating for combined interventions.
glp-1ra
incretin
obesity
overweight
weight-loss
lifestyle-intervention